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Abstract
The establishment of metastasis depends on the ability of cancer cells to acquire a migratory
phenotype combined with their capacity to recreate a secondary tumor in a distant tissue. In epithelial
cancers, such as those of the breast, the epithelial-mesenchymal transition (EMT) is associated with
basal-like breast cancers, generates cells with stem-like properties, and enables cancer cell
dissemination and metastasis. However, the molecular mechanism(s) that connects stem cell–like
characteristics with EMT has yet to be defined. Using an orthotopic model of human breast cancer
metastasis to lung, we identified a poor prognosis gene signature, in which several components of
the wnt signaling pathway were overexpressed in early lung metastases. The wnt genes identified in
this signature were strongly associated with human basal-like breast cancers. We found that inhibiting
wnt signaling through LRP6 reduced the capacity of cancer cells to self-renew and seed tumors in
vivo. Furthermore, inhibition of wnt signaling resulted in the reexpression of breast epithelial
differentiation markers and repression of EMT transcription factors SLUG and TWIST. Collectively,
these results provide a molecular link between self-renewal, EMT, and metastasis in basal-like breast
cancers.
Introduction
Breast cancer relapse and subsequent metastatic spread to distant sites, such as lung, liver,
brain, and bone, remain the leading cause of morbidity and mortality associated with the
disease. Metastasis is thought to be an inefficient process because many thousands of cancer
cells are shed into the circulation, yet only a very few have the ability to form distant nodules
(1). Because a rare population of cells in human breast cancers have been identified with the
capacity to self-renew, produce differentiated daughter cells, and form tumors in
immunocompromised mice, these cells are natural candidates to seed metastasis (2,3).
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However, little is known about the relationship between the cells that seed and initiate primary
tumor growth with those that exhibit metastatic potential and likely seed secondary tumors.
Much recent work has focused on identifying the genetic factors in cancer cells that mediate
their migration or propensity to associate with certain tissues in advanced stages of malignancy
(4–7). This work has revealed the important role of cell surface molecules, growth factors,
extracellular matrix molecules, and proteases as critical components for breast cancer cell
tropism and adhesion in certain distant tissues (8). In addition, metastasis has been linked to
the expression of embryonic transcription factors (TWIST, SLUG), which promote the
migratory and invasive state called the epithelial-to-mesenchymal transition (EMT; refs. 9–
11). In an EMT state, epithelial cells lose expression of many markers of differentiation, acquire
migratory and mesenchymal features, and exhibit enhanced tumor seeding (12). However, the
molecular link between EMT and self-renewal is unclear; whether a shared signaling pathway
regulates both processes is unknown.
The wnt signaling pathway mediates a wide variety of processes, including cell proliferation,
migration, differentiation, adhesion, and death (13). Furthermore, wnt signals have been
reported to promote migration and EMT in breast cancer cells through stabilization of Snail
(14). Consistent with this notion, wnt signaling up-regulates the transcription factors Slug and
Twist (15,16), which are both known to be transcriptional repressors of E-cadherin.
The Wnt pathway is composed of two distinct signaling arms: the canonical and noncanonical
pathways. In the canonical pathway, the wnt protein binds to the cell surface receptor Frizzled,
which uses the coreceptors Lrp5/6 to promote Axin binding to Dishevelled. This leads to the
stabilization of β-catenin, which in turn translocates to the nucleus, where it interacts with the
DNA-binding proteins from the Tcf/Lef family to activate transcription of an extensive array
of genes (17). SFRP1, a negative regulator of wnt signaling, is a member of the family of
secreted frizzled-related proteins. These proteins are homologous to the extracellular cysteine-
rich domain of the wnt receptor frizzled, thereby preventing wnt ligands from binding (18).
DKK1 is another secreted inhibitor that functions by binding directly to the Lrp5/6 coreceptors
and inhibiting canonical wnt signal transduction (19). Recent studies report that secreted
inhibitors of the wnt pathway, including both SFRP1 and DKK1, are frequently silenced by
methylation in many human cancers, including breast cancer (20).
Currently, human tumor models used to study breast cancer metastasis to lung rely on
introducing cancer cells directly into the vasculature by injection into the tail vein (4,21,22).
Whereas these models are useful for identifying and examining factors involved in proliferation
of breast cancer cells that have been directly deposited into the lung environment, they do not
model all the events necessary for the metastatic process from the primary site.
Given these limitations, we sought to develop a model of breast cancer metastasis that more
faithfully recapitulates the biology and progression of the disease when implanted into the
orthotopic site. Accordingly, we tested several different human breast cancer cell lines for their
ability to spontaneously metastasize after primary tumor growth in the mammary fat pads of
NOD/SCID immuno-deficient mice. One cell line, SUM1315, showed the propensity to
metastasize to mouse lung and human implanted bone after primary tumor development (23).
In this report, we set out to identify genes that mediate breast cancer metastasis to lung and, in
doing so, identified various components of the wnt signaling pathway that are overexpressed
in lung micrometastases. We reasoned that wnt signaling might be regulating cancer cell self-
renewal and expression of EMT transcription factors, thereby enabling tumor seeding and
metastasis. We show herein the effects of inhibiting wnt signaling on cancer cell differentiation
states through the expression of the EMT transcription factors Slug and Twist and reveal how
this pathway links the EMT state with differentiation, self-renewal, and tumor formation.
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SUM1315 cells (obtained from Dr. Stephen Ethier, Michigan) were cultured in Ham’s F12
supplemented with 5% fetal bovine serum, insulin (5 µg/mL), and epidermal growth factor (10
µg/mL; see ref. 3 for culturing of other cell lines). Virus was produced as described previously
(24).
Real time PCR
RNA was isolated and purified using QIAGEN RNAeasy kit for cells in culture and Trizol
reagent (Invitrogen) for whole tissue. RNA was reverse transcribed to cDNA using Bio-Rad
iScript cDNA synthesis kit. Quantitative real-time PCR analysis was performed using SyBR
Green (Bio-Rad). Custom-designed differentiation arrays were purchased from Superarray
(gene list in Supplementary Table S4, catalogue CAPH-0298A). RNA was isolated using the
QIAGEN RNAeasy kit. cDNA was prepared using the RT2 First Strand kit, and PCR analysis
was performed using Superarray SyBr Green Master Mix. Fold differences were calculated
using the software supplied on the Superarray website. Heatmap Builder software was used to
create heatmap. Primer sequences used for quantitative real-time PCR are in Supplementary
Table S5.
Microarray analysis
Total RNA was collected using Trizol on three fragments of tumor tissue and three fragments
of associated lung metastases from four different mice. Total RNA (2 µg) from each pooled
sample was hybridized to the Operon human 27K oligonucleotide (70-mer) array chip, which
contains 26,791 transcripts representing over 20,000 human genes as previously described
(25).
Luciferase assays
Cells were plated in 12-well plates 24 h before transfection. TOPFlash or FOPFlash (150 ng)
and Renilla (1 ng) were transfected using FuGene 6 (Roche) according to the manufacturer’s
protocol. Wnt3a conditioned media and control conditioned media were added 24 h
posttransfection, and luciferase readings were recorded 48 h posttransfection using Promega’s
dual-luciferase reporter assay system according to instructions. Luciferase readings were
recorded using a Zylux FB12single tube luminometer. Experiments were performed in
triplicate on at least three separate days. TOPFlash, FOPFlash, and Wnt1 plasmids were gifts
from Dr. Amy Yee (Tufts).
In vivo experiments
Female NOD/SCID mice were injected between 6 and 12wk of age into the fourth inguinal
mammary gland. Cells were resuspended in 3:1 media/Matrigel solution and injected at one
million cells per gland. Mice were monitored weekly until palpable tumors formed, and tumor
growth was measured and recorded using calipers at least once per week thereafter. Tissues
were embedded in paraffin and H&E stained at Tufts Medical Center.
Spheres
Cells were plated onto 6-cm nonadherent plates (Corning) at 50,000 cells/mL. Visible spheres
were counted on day 6 postplating. SUM1315-shLrp6 spheres, and the respective empty vector
control were counted by straining through a 40-µm filter, eluting onto a dish with a grid and
counting under a microscope.
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Protein was extracted from cells in culture using radioimmunoprecipitation assay buffer and
from tumors using a Brij lysis buffer supplemented with protease inhibitors. Membranes were
probed using the following antibodies: sFRP1 (AbCam), Dkk1 (Santa Cruz), active β-catenin
(AbCam), glyceraldehyde-3-phosphate dehydrogenase (Chemicon), caspase-3 (Cell
Signaling), smooth muscle actin (Vector), β-actin (Abcam), Lrp6 (Cell Signaling), SOX17
(R&D), Twist (Cell Signaling), and Slug (Cell Signaling).
Growth curves
Eight thousand cells were plated in triplicate in 24-well plates. Cells were trypsinized on days
recorded in graph and counted using a Coulter Counter. Each well was counted thrice and
repeated on three separate days.
Immunohistochemistry
Slides were deparaffinized and rehydrated in graded ethanols from 100% to 70%. Antigen
retrieval was performed by boiling slides for 20 min using 10 mmol/L citrate (pH 6.0). Slides
were blocked with 1% bovine serum albumin/serum, and primary antibody (Slug, Cell
Signaling) was used at 1:50 overnight at 4°C. Secondary antibodies were detected using avidin-
biotin complex kit, and signal was developed using Nova Red (Vector Labs.). Slides were
dehydrated and coverslipped.
Results
Identification of a wnt signaling signature in an orthotopic model of lung metastases
The SUM1315 cell line was derived from a cutaneous metastatic nodule from a patient with
advanced invasive breast ductal carcinoma (23) that forms poorly differentiated, highly
invasive tumors with 90% (29 of 32) efficiency and exhibits patterns of intravascular and
intralymphatic growth within the mammary glands of mice (Fig. 1A). We engineered the
SUM1315 cells to express green fluorescent protein (GFP) to visualize distant tissues for the
presence of metastatic GFP+ breast cancer cells. Similar to parental SUM1315 cells,
SUM1315-GFP cells metastasize to lung in ~30% (6 of 19) of animals and to brain in ~20%
(one of five) of animals (Fig. 1A). SUM1315 is an ER/PR/Her2-negative basal-type breast
cancer model that exhibits hallmarks of EMT, including loss of E-cadherin and epithelial
keratin expression, and acquisition of Vimentin and fibronectin expression. Furthermore,
SUM1315 cells express the EMT transcription factors SLUG and TWIST (Fig. 1A; refs. 23,
26).
We used this model system to identify patterns of gene expression associated with metastatic
behavior. Accordingly, we performed a microarray study on primary breast tumor tissues from
mice bearing SUM1315 xenografts compared with their corresponding lungs harboring visible
GFP+ lung micrometastases (Fig. 1B). To minimize selection bias and animal-to-animal
variability, three fragments of each tumor tissue and three fragments of associated lung
metastases were collected and pooled together from four separate animals, respectively. A list
corresponding to genes differentially expressed between lung metastases and primary tumors
was generated. In total, 784 genes were differentially expressed in lung metastases compared
with primary mammary tumors (Supplementary Table S1).
We next assessed whether this gene signature was associated with clinical outcome or with
biological relevance. Using the van’t Veer poor prognosis data set (27), we classified each
patient based on tumor outcome and then performed rank order splitting analysis with the genes
differentially expressed in lung metastases compared with the primary tumors. Remarkably,
this lung metastasis signature was significantly associated with poor prognosis (Supplementary
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Fig. S1A; P = 0.001), reduced time to metastasis (Supplementary Fig. S1A; P = 0.002), and
reduced overall survival (Supplementary Fig. S1; P = 0.001). Because the SUM1315 line is a
basal-like breast cancer tumor model, we next examined whether the lung metastasis signature
could be used to classify breast cancers according to tumor subtype. However, in contrast to
patient outcome, this lung signature was not robustly associated with tumor subtype
classification (data not shown).
Functional gene ontology classification of differentially expressed genes revealed that the lung
signature was enriched for genes involved in development, metabolism, and cell death
(Supplementary Table S2). The gene list was classified by signaling pathways to identify those
that might be important in metastasis biology. Remarkably, the most abundantly represented
signaling pathway identified in the lung metastatic signature was the Wnt pathway (Fig. 1C),
in which 13 wnt genes representing 49 signaling components were differentially expressed.
These genes included the cell surface receptors LRP5 and FZD9, as well as the wnt target genes
WISP2 and CCND3 (Supplementary Table S3). An additional eight wnt pathway genes were
identified in the lung metastasis signature that were differentially expressed 1.4-fold, including
AXIN2, DVL2, WNT7A, and engrailed (Supplementary Table S3). Several of the genes that
were differentially expressed 1.4-fold was validated by quantitative reverse transcription–PCR
(qRT-PCR; Supplementary Fig. S2).
Interestingly, this wnt gene list was significantly correlated with basal-like breast cancers using
both the NKI and UNC data sets (refs. 27–29; P = 0.0001 and 0.0006; Supplementary Fig. S1).
We also found that several of these wnt genes were associated with poor prognosis, high-grade,
metastatic breast cancer (Table 1; ref. 30). Collectively, these data are consistent with and
support recent findings that wnt signaling is up-regulated in human basal subtype breast cancers
and lung and brain metastasis (31).
Wnt signaling through LRP6 is required for tumor formation and metastasis
Whereas mutations in the wnt pathway (e.g., APC) are well known for their causal role in the
progression of colon cancer (32), mutations in the wnt pathway have not been identified in
breast cancer (33). Despite the lack of genetic mutations, β-catenin is observed in both the
cytoplasm and nucleus of many human breast cancer specimens, indicating activation of the
pathway (33). Additionally, many negative regulators of the pathway, including SFRP1 and
DKK1, are often silenced in breast cancer, a possible contributing factor for the unopposed wnt
activity in breast cancer (20). Therefore, we assessed wnt signaling activity of a number of
breast cancer cell lines, including SUM1315, SUM149, SUM159, MDA.MB.231, MCF7, and
T47D using the TOPFLASH reporter assay. Interestingly, SUM1315 cells, which are capable
of completing all the steps necessary for metastasis, exhibited elevated wnt activity in the
absence of exogenous wnt stimulation compared with other breast cancer cell lines
(Supplementary Fig. S2). Whereas it is unclear whether the SUM1315 cells exhibited the most
robust TOPFLASH activity due to further mutations in the wnt pathway or produce elevated
levels of wnt ligands compared with the other cell lines, these results support the microarray
results above correlating wnt signaling with metastatic behavior.
Given these findings, we speculated that inhibition of wnt signaling in SUM1315 cells might
affect their ability to form tumors or metastasize. We therefore generated SUM1315 cells that
overexpress either SFRP1 or DKK1 (Fig. 2A). SUM1315 cells normally express moderate
endogenous DKK1, yet protein expression and secretion into the supernatant were increased
upon its ectopic expression in SUM1315-DKK1 cells (Fig. 2A). In contrast, SUM1315 cells
do not express endogenous SFRP1 mRNA or protein (Fig. 2A; data not shown), consistent with
its methylation (34–36), but SUM1315-SFRP1 cells produce abundant message and protein
(Fig. 2A; data not shown). We confirmed that enforced expression of DKK1 and SFRP1
inhibited wnt signaling using the TOPFlash reporter system to assess wnt/β-catenin activity.
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Exogenous Wnt1 ligand stimulated robust TOPFlash activity in control SUM1315 cells but
was blocked in cells overexpressing SFRP1 or DKK1 (Fig. 2B).
We next injected one million SUM1315-SFRP1 and DKK1 cells into the mammary fat pads
of NOD/SCID to determine if inhibition of wnt signaling would affect the ability to seed tumors
and/or metastasize in mice. SUM1315 cells expressing the empty-vector control or
overexpressing SFRP1 formed primary mammary tumors and metastases at similar rates and
with identical frequencies (Fig. 2C). In contrast, cells overexpressing DKK1 failed to form
palpable tumors or metastases even by 100 days postinjection (Fig. 2C).
Because tumor formation and lung colonization were not affected in cells overexpressing
SFRP1, we tested for the possibility that ectopic SFRP1 expression was lost in the cells that
formed tumors in vivo. However, we confirmed that tumor tissues growing in mice from SFRP1
expressing SUM1315 cells still retained robust SFRP1 mRNA and protein expression
(Supplementary Fig. S3). Therefore, we reasoned that the differences in tumor formation by
DKK1 and SFRP1-expressing cells was likely due to the difference in the mechanism by which
these inhibitors function rather than due to silencing of the gene.
SFRPs exert their inhibitory effects through binding to wnt ligands and preventing their binding
to the frizzled receptors. This raised the possibility that ectopic SFRP1 expression might not
adequately inhibit wnt ligands produced in vivo by the stromal microenvironment. To test this
possibility, we examined wnt activity while stimulating cells with conditioned media collected
from mouse stromal fibroblasts expressing Wnt3a. Wnt3a conditioned media induced robust
TOPFlash activity in control SUM1315 cells, which was efficiently blocked in cells
overexpressing DKK1. However, SFRP1-expressing cells were unable to block wnt3a-
stimulated TOPFlash activity (Fig. 2C versus B). Moreover, wnt3a-treated SFRP1-SUM1315
cells exhibited similar gene expression changes as the control SUM1315 cells treated with
wnt3a conditioned media (Supplementary Fig. S4). These results imply that the ability of
SUM1315-SFRP1 cells to form tumors was due to incomplete inhibition of wnt signaling in
vivo.
DKK1 exerts its wnt inhibitory activity by binding directly to the LRP5/6 coreceptor and
inhibiting its interaction with frizzled (19). Thus, if DKK1 was inhibiting wnt-signaling through
its effects on LRP6, knockdown of the receptor should phenocopy cells overexpressing
DKK1. Stable lentiviral integration of hairpins against LRP6 resulted in ~50% reduction in
mRNA levels (Fig. 2D) and undetectable protein expression by immunoblotting (Fig. 2D;
protein expression of LRP5 was undetectable by Western blot; data not shown). LRP6 short
hairpin RNA (shRNA) cells injected into the mammary fat pads of NOD/SCID mice also failed
to form tumors indicating that DKK1 overexpression likely inhibits primary tumor formation
through its effects on LRP6 (Fig. 2D). Collectively, these data show that wnt signaling through
LRP6 is required for tumor formation.
Wnt signaling is necessary for cancer cell self-renewal but not proliferation
To determine the mechanism by which wnt inhibition blocked tumor formation, we examined
the effects of wnt inhibition on cell proliferation in vitro. SUM1315 control cells, as well as
cells overexpressing SFRP1, DKK1, or shRNA against LRP6, grew at similar rates in vitro,
indicating that wnt is not required for the proliferation of SUM1315 cells in culture (Fig. 3A).
Sphere formation in nonadherent cultures is reflective of stem-like properties, including the
ability to survive suspension-induced cell death, and is a predictor of tumor formation in
vivo (3,12). We and others have previously shown that tumorsphere formation in vitro
correlates with tumorigenicity in vivo (3). Interestingly, despite not affecting proliferation,
overexpression of SFRP1, DKK1, or knockdown of LRP6 resulted in a reduction in sphere-
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forming ability (Fig. 3B). In addition, the differences in sphere forming ability were not due
to differences in apoptosis, as cleaved caspase-3 expression levels were similar in DKK1-
overexpressing cells compared with control cells (Fig. 3C). Given this finding and the fact that
the wnt pathway is a critical regulator of self-renewal in other systems, we reasoned that the
decrease in sphere formation may be an indication of defects in self-renewal.
Therefore, we used the serial colony-forming unit (CFU) assay to analyze the effect of wnt
inhibition on self-renewal. A cell line capable of self-renewal should exhibit an increase in the
number of colonies formed after serially passaging in culture. This was indeed observed with
the SUM1315 control cell line but also for the SFRP1-SUM1315, which had expanded upon
the third serial passage (Fig. 3D). By contrast, the DKK1-SUM1315 line had failed to increase
the number of colonies formed after serial passaging, indicating that self-renewal was impeded.
It has been shown that sphere formation, basal-like breast cancers, and EMT (epithelial
dedifferentiation) correlate with a CD44hi/CD24lo antigen phenotype (3,12,37,38). Because
the SUM1315 cell line already exhibits a high CD44hi/CD24lo profile (3,38), we wanted to
determine whether this phenotype was altered in response to overexpression of DKK1. We
indeed found that expression of DKK1 increased the proportion CD44lo/CD24lo by 50%
(Supplementary Fig. S5). Taken together, these data imply that wnt signaling is necessary for
cancer cell self-renewal and regulation of cell differentiation phenotypes independent of
proliferation and apoptosis.
Wnt signaling maintains the dedifferentiated EMT state
As previously mentioned, the SUM1315 line is a mesenchymal/basal cell line that expresses
high levels of the EMT transcription factors Slug and Twist (Fig. 1A; ref. 26). SLUG is a
reported wnt target gene (39,40), whereas Twist has been shown to be up-regulated in response
to Wnt1 stimulation (16). Based on the recent findings that ectopic expression of EMT
transcription factors, including TWIST, could enhance tumorigenicity (12), we wished to
determine whether the effects of wnt inhibition on tumor seeding might be through the
expression of EMT genes. Accordingly, SUM1315 cells treated with DKK1 exhibited a dose-
dependent reduction in mRNA expression and protein levels of both Slug and Twist (Fig. 4A
and B). In contrast, expression levels of Sox17, a transcription factor not targeted by wnt
signaling, was unaffected by treatment with DKK1 (Fig. 4C), indicating that the reduction in
expression of Slug and Twist were specifically due to inhibition of wnt signaling.
Because the EMT transcription factors SLUG and TWIST were reduced upon DKK1 treatment,
we reasoned that such cells would display features of epithelial differentiation and lineage
commitment. We, therefore, examined the differentiation state of the wnt-inhibited lines using
a custom qRT-PCR array targeting 86 genes known to be associated with either myoepithelial,
luminal epithelial, or mammary epithelial stem cell differentiation (Supplementary Table S4).
Remarkably, all the wnt-inhibited cell lines exhibited an increased mRNA expression of
mammary epithelial markers, including those of committed luminal (KRT18, EPCAM,
GATA3, PRLR) and myoepithelial cells (TTHY1, ACTA2; Fig. 4D). Expression of α-smooth
muscle actin (ACTA2), a marker of mature differentiated myoepithelial cells, was further
confirmed by immunoblotting (Fig. 4D). These results indicated that wnt signaling was
necessary for the maintenance of a dedifferentiated epithelial phenotype consistent with EMT.
Reexpression of EMT transcription factors in vivo bypasses wnt inhibition
The EMT state generates cells with many of the properties of self-renewing stem cells,
including suppression of epithelial differentiation and the ability to seed tumors in vivo (12,
24). Because SLUG and TWIST were reduced upon DKK1 treatment, we, therefore, wanted to
determine whether the lack of tumor seeding in SUM1315-DKK1 cells was a consequence of
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repressed SLUG or TWIST expression. To this end, one million SUM1315-DKK1 cells were
injected orthotopically into NOD/SCID female mice. Whereas tumors did not form in any
animal by 100 days postinjection, tumorigenic clones eventually escaped and tumors developed
in 50% of the mice (“escaped”); the other 50% of the mice still had not formed palpable tumor
masses (“inhibited”) within this time. We speculated that if the expression of Slug and Twist
facilitates tumor growth, then tumor cells, which had eventually escaped wnt inhibition, would
have reexpressed such transcription factors. To test this hypothesis, tumors and injection sites
were harvested and examined for expression of DKK1, TWIST, and SLUG. Whereas all
“escaped” and “inhibited” DKK1 tumors maintained robust mRNA and protein expression of
DKK1 (Fig. 5A; data not shown), we observed reexpression of Slug and Twist only in the
escaped DKK1-SUM1315 tumors compared with the inhibited DKK1-SUM1315 tumors (Fig.
5B and C). Furthermore, the escaped DKK1-SUM1315 tumors exhibited high levels of active
β-catenin, an indication that the wnt–β-catenin pathway had been reactivated despite DKK1
expression (Fig. 5C). Taken together, these data suggest that inhibition of wnt signaling blocks
tumor formation by promoting epithelial differentiation and repressing transcriptional
repressors.
Discussion
Several studies have documented EMT in enabling both tumor seeding at low dilutions and
lung metastasis (12,41). Our results provide evidence of a unifying signaling pathway that
mediates both of these processes. Wnt signaling through LRP6 in a model of basal-like breast
cancer repressed cancer cell differentiation and induced the expression of the EMT
transcription factors Slug and Twist. Ectopic expression of DKK1 affected wnt signaling by
inactivation of the LRP6 receptor, leading to a reduction in tumor formation and survival in
suspension culture. DKK1 also reduced expression of Slug and Twist that was attendant with
reexpression of epithelial characteristics. Because Slug and Twist are regulators of EMT, our
results imply that wnt signals integrate cell fate decisions with differentiation and cell behavior
(Fig. 5D).
In addition to identifying a molecular link between EMT, differentiation, and metastasis, these
data also validate the use of the SUM1315 model of human breast cancer metastasis from the
orthotopic site and the identification of genes mediating breast cancer metastasis to the lungs.
Interestingly, very few of the genes identified using this model system overlapped with the
lung metastasis signature previously reported (21). However, this is likely due to the significant
differences in model systems and experimental designs. Previous studies used serial passaging
of MDA.MB.23l cells after tail vein injection to generate subpopulations of MDA.MB.23l cells
with increased ability for lung colonization. In addition, transcriptional profiling compared the
in vitro cultured lung-selected clones to the in vitro cultured parental MDA.MB.231 cell line.
By contrast, we used a heterogeneous population of cells and performed microarray analysis
on the fresh primary tumor tissues compared with fresh lung metastases. Because it has been
shown that profiling of MDA.MB.231 cells grown in culture compared with the same cells
injected into the mammary fat pad of mice results in profound differences (42), the
transcriptome profiling of the MDA.MB.231 subpopulations likely represent a small set of the
potential genes differentially expressed in lung metastasis and poor prognosis tumors.
The inhibition of wnt signaling in SUM1315 cells affected tumor growth, thereby precluding
the examination of lung metastasis in wnt-inhibited cells. However, previous studies have
shown that reduction in Slug and/or Twist expression reduces lung metastasis in vivo (24,41).
Therefore, it would seem likely that cells that cannot seed a primary tumor will likely be unable
to seed a secondary tumor as well. Taken together with the data presented here, this implies
that wnt signaling can regulate cell-cell adhesion, and cell behaviors that are characterized by
EMT through its effects on Slug and Twist but can also connect EMT with cell fate and
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differentiation. Hence, it will be of great importance to determine whether pharmacologic or
antibody-based therapies targeting the wnt pathway will affect tumor recurrence and/or
metastasis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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A, orthotopic xenograft model of human breast cancer metastasis. i, phase contrast image of
SUM1315 cells in culture. ii, H&E-stained section of SUM1315 xenograft (BV, blood vessel).
iii, Vimentin-stained section of SUM1315 xenograft. Human tumor cells are Vimentin positive,
whereas surrounding mouse stroma is Vimentin negative. iv, H&E-stained section of mouse
mammary tissue. The tumor has invaded and replaced most of the normal lymph node tissue.
v, GFP image of nodules in lung tissues resulting from a SUM1315 primary tumor. vi, GFP
image of metastasis in brain resulting from a SUM1315 primary tumor. GFP-positive cells are
tumor cells. vii, H&E-stained section of lungs harvested from mice bearing SUM1315 tumors.
Arrows point to metastases. viii, SUM1315 xenograft primary tumor stained with Slug. B,
schematic representation of microarray study. GFP images (top) and H&E-stained sections
(bottom) of primary tumor and lung metastasis from SUM1315 injections. C, left, lung
metastasis gene list (Supplementary Table S1) was compared with van’t Veer poor prognosis
data set and is associated with reduced time to metastasis. Middle, pathway analysis of genes
identified in lung metastasis signature using the PANTHER database. Wnt gene list
(Supplementary Table S3) was compared with published microarray. Right, Wnt gene list was
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compared with UNC12 data set (Supplementary Fig. S1) and is significantly correlated with
basal-like breast cancers.
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DKK1 inhibits primary tumor growth through inhibition of LRP6. A, Western blot analysis of
whole-cell lysate and conditioned media collected from control empty vector (EV), SFRP1, or
DKK1-overexpressing cells. B, TOPFlash assay of EV-SUM1315, SFRP1-SUM1315, and
DKK1-SUM1315 cells in the absence and presence of Wnt1. C, tumor growth curves of
SUM1315 cells overexpressing SFRP1, DKK. Error bars, SE. H&E stained of primary tumor
and matched lung from mouse injected with SFRP1-SUM1315 cells. m, metastasis; a, alveolus
TOPFlash assay of Control-SUM1315, SFRP1-SUM1315, and DKK1-SUM1315 cells
stimulated by wnt3a-conditioned media. D, qRT-PCR analysis of RNA extracted from stable
Lrp6 knockdowns. Error bar, SD. Western blot analysis of several Lrp6 stable knockdowns
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compared with the control EV and scrambled control. Tumor growth curves of SUM1315
expressing shLrp6 3405. Error bars, SE.
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Wnt signaling is necessary for survival in suspension, but not proliferation. A, growth curve
analysis of wnt-inhibited (SFRP1, DKK1, and shLrp6 lines) and control SUM1315 cell lines.
B, tumorsphere formation of control-SUM1315, SFRP1-SUM1315, and DKK1-SUM1315
cells. Error bars, SD. C, Western blot for caspase-3. Protein lysates were collected from
adherent monolayers (lanes 2 and 3) or cells grown in suspension (lanes 4 and 5). The positive
control (lane 1) was SUM1315 cells treated with 5-fluorouracil (1 mmol/L) for 6 d. D, serial
CFU assays of SUM1315-EV, SFRP1, and DKK1 cell lines plated at low dilutions. Colonies
were defined as having >30 cells.
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Wnt signaling represses differentiation. Western blot and qRT-PCR analysis for Slug (A), Twist
(B), and SOX17 (C) in SUM1315 cells transfected with DKK1. D, differential gene expression
of differentiation genes from wnt-inhibited cell lines. Heatmap Builder Software was used to
analyze the data. Starred (*) genes represent those of myoepithelial differentiation, whereas
unstarred genes represent luminal differentiation. Western blot analysis of α-smooth muscle
actin expression in Control-SUM1315, SFRP1-SUM1315, and DKK1-SUM1315 cells to
confirm the qRT-PCR results from left.
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Reexpression of Slug and Twist in vivo bypasses wnt inhibition. A, qRT-PCR analysis of DKK1
expression in tumor and injection sites from mammary glands of mice injected with control
SUM1315-EV or DKK1-expressing cells. B, Western blot analysis of Twist and Slug
expression in tumors and injection sites isolated from mice injected with SUM1315-Control
EV or DKK1 expressing cells. C, Western blot analysis of DKK1 and SFRP1 tumors for active
β-catenin and Slug. D, schematic model of wnt in breast epithelial differentiation, EMT, and
metastasis. In the absence of wnt signaling (left; or in the presence of wnt inhibitors), cells
undergo lineage commitment and differentiation. In the presence of wnt signals, β-catenin
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partners with TCF/LEF to activate target genes, such as SLUG and TWIST, which promote
an EMT, repress differentiation, and enhance tumor seeding and metastasis.
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Table 1
Wnt pathway genes expressed in human breast cancer
Gene Analysis P Study name and reference
NFATc3 (a) Poorly differentiated 4.50E–05 Desmedt (43)
(b) Death within 5 y 1.70E–04 Pawitan (44)
(c) Relapse/recurrence in 5 y 5.70E–04 van de Vijver (45)
CCND3 (a) Adjuvant hormone 3.90E–04 Sotiriou (46)
(b) BRCA1 positive 0.001 van ’t Veer (27)
(c) Basal-like 0.005 Richardson (47)
WISP2 (a) Positive lymphocytic infiltrate 1.80E-04 van ’t Veer (27)
(b) Grade 3 3.6E-4 and 3.60E-04 Ivshina (48)
FZD9 (a) BRCA1 positive 1.10E-04 van ’t Veer (27)
(b) Grade 3 1.60E-04 van ’t Veer (27)
(c) Poorly differentiated 9.40E-04 Desmedt (43)
(d) Positive lymphocytic infiltrate 0.001 van ’t Veer (27)
HDAC1 (a) aggressive lung metastasis 0.008 Minn (21)
LRP6 (a) Basal type carcinoma 3.5 E-5 Richardson (47)
(b) Invasive ductal and invasive lobular carcinoma 1.6 E-4 Desmedt (43)
EN1 (a) Basal-like carcinoma 1.9E-11 and 5.2E-6 Farmer (49)
(b) Response to chemo 5.80E-04 Hess (50)
(c) Poorly differentiated 7.70E-04 Desmedt (43)
HOXA7 (a) Elston Grade 3 3E-6 and 5.9E-6 Ivshina (48)
(b) Bone Metastases 0.004 Ma (51)
(c) Positive lymph nodes 0.003 and 0.006 Miller (52)
CDH23 (a) BRCA1 tumors 2.90E-04 van ’t Veer (27)
(b) Lymphocytic infiltrate 0.003 van ’t Veer (27)
MYCL1 (a) Lobular Carcinoma 0.003 Ma (51)
(b) After chemotherapy 0.007 Sørlie (53)
HOXD4 (a) PR positive 2.40E-05 Minn (21)
(b) Aggressive Lung Metastasis 0.006 Minn (21)
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